VOLITIONRX LTD·4

Feb 27, 4:31 PM ET

Hughes Terig 4

Research Summary

AI-generated summary

Updated

VOLITIONRX (VNRX) CFO Hughes Terig Receives 202,000 RSUs

What Happened Hughes Terig, the Chief Financial Officer of VolitionRx Ltd (VNRX), was granted 202,000 restricted stock units (RSUs) on February 26, 2026 under the company’s 2024 Stock Incentive Plan. The RSUs were awarded in lieu of cash compensation and are recorded at an acquisition price of $0.00 (i.e., no cash paid). These RSUs will be earned in twelve approximately equal monthly installments beginning March 1, 2026 and, after being earned, remain subject to additional time-based vesting in a single installment on February 26, 2027. Upon vesting and settlement, each earned RSU converts into one share of common stock.

Key Details

  • Transaction date: February 26, 2026; Form 4 filed February 27, 2026 (appears timely).
  • Transaction type/code: Award/Grant (A); 202,000 RSUs granted at $0.00 acquisition price (total reported dollar value $0).
  • Vesting/earnings schedule: Earned in 12 approximately equal monthly installments starting March 1, 2026; after earning, all remaining time-based vesting occurs on February 26, 2027; continued service required for each earning and vesting date.
  • Shares owned after transaction: Not specified in the filing.
  • Footnote: RSUs were granted in lieu of cash compensation (see footnote F1).

Context RSU grants are a form of compensation deferral, not an open-market purchase or sale. They only become actual shares if and when the RSUs are earned and subsequently vest; until settlement they do not represent immediately tradable shares. Grants in lieu of cash are common for executive compensation and do not by themselves indicate the insider is buying or selling stock on the market.